Preface – Special Issue: A Tribute for Prof. Dr. Melvin D. Yahr, M.D. (1917–2004) P. Riederer OriginalPaper Pages: 1205 - 1208
Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia A. Mouatt-PrigentM.-P. MurielE. C. Hirsch OriginalPaper 13 April 2004 Pages: 1209 - 1218
Lewy body-related α-synucleinopathy in the aged human brain K. A. Jellinger OriginalPaper 02 April 2004 Pages: 1219 - 1235
Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress C. MytilineouK. St. P. McNaughtC. W. Olanow OriginalPaper Pages: 1237 - 1251
Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells M. Shamoto-NagaiW. MaruyamaM. Naoi OriginalPaper Pages: 1253 - 1265
Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration A. StorchA. C. LudolphJ. Schwarz OriginalPaper Pages: 1267 - 1286
Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions D. J. ZgaljardicN. S. FoldiJ. C. Borod OriginalPaper 07 July 2004 Pages: 1287 - 1301
Cognitive dysfunction and dementia in Parkinson’s disease J. L. W. BosboomD. StoffersE. Ch. Wolters OriginalPaper 30 June 2004 Pages: 1303 - 1315
Nicotinic receptors and cognition in Parkinson’s Disease: the importance of neuronal synchrony P. B. ForgacsI. Bodis-Wollner OriginalPaper 30 June 2004 Pages: 1317 - 1331
Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD) C. E. MorrisonJ. C. BorodC. W. Olanow OriginalPaper 12 May 2004 Pages: 1333 - 1341
Clinical advantages of COMT inhibition with entacapone – a review A. GordinS. KaakkolaH. Teräväinen OriginalPaper 03 August 2004 Pages: 1343 - 1363
Antiapoptotic effects of budipine T. MüllerH. PrzuntekA. Mackowiak OriginalPaper 17 May 2004 Pages: 1365 - 1373
Dopamine receptor agonists in the therapy of Parkinson’s disease P. FoleyM. GerlachP. Riederer OriginalPaper 29 December 2003 Pages: 1375 - 1446
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease D. MerimsH. ShabtaiN. Giladi OriginalPaper Pages: 1447 - 1453
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases M. B. H. YoudimM. FridkinH. Zheng OriginalPaper 20 April 2004 Pages: 1455 - 1471
Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort C. PeraltaP. WernerW. Poewe OriginalPaper 03 August 2004 Pages: 1473 - 1483
Huntington’s disease: pathomechanism and therapeutic perspectives G. GárdiánL. Vécsei OriginalPaper Pages: 1485 - 1494
Functional imaging in Tourette’s syndrome J. R. AdamsA. R. TroianoD. B. Calne OriginalPaper 30 June 2004 Pages: 1495 - 1506